Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kairos Pharma, Ltd. Common Stock
(NY:
KAPA
)
0.8670
+0.0140 (+1.64%)
Official Closing Price
Updated: 8:00 PM EDT, Apr 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kairos Pharma, Ltd. Common Stock
< Previous
1
2
Next >
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Secures DoD Grant to Advance Lung Cancer Biomarker Research
April 24, 2025
Via
Investor Brand Network
Kairos Pharma Ltd. Provides Letter to Stockholders
April 24, 2025
From
Kairos Pharma, Ltd
Via
Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Secures DoD Grant to Advance Lung Cancer Biomarker Research
April 17, 2025
Via
Investor Brand Network
Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer
April 17, 2025
From
Kairos Pharma, Ltd
Via
Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Completes Safety Lead-In for Phase 2 Prostate Cancer Trial
March 31, 2025
Via
Investor Brand Network
Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
March 31, 2025
From
Kairos Pharma, Ltd
Via
Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Gains Traction with Conference Participation and Analyst Coverage
March 28, 2025
Via
Investor Brand Network
Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events
March 27, 2025
From
Kairos Pharma, Ltd
Via
Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Publishes Findings on Overcoming NSCLC Drug Resistance
March 20, 2025
Via
Investor Brand Network
Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer
March 20, 2025
From
Kairos Pharma, Ltd
Via
Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Presents Positive Preclinical Data on KROS 101 and KROS 401 at AACR IO Conference
February 26, 2025
Via
Investor Brand Network
Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma
February 26, 2025
From
Kairos Pharma, Ltd
Via
Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Secures $600K in Funding for ENV205 Development
February 18, 2025
Via
Investor Brand Network
Kairos Pharma Announces New Department of Defense Funding for Research of ENV205
February 18, 2025
From
Kairos Pharma, Ltd
Via
Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Adds Huntsman Cancer Institute to Phase 2 Trial for Prostate Cancer Therapy
February 11, 2025
Via
Investor Brand Network
Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial
February 11, 2025
From
Kairos Pharma, Ltd
Via
Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Preclinical Data on GITR Agonist KROS 101 at AACR-JCA Conference
February 06, 2025
Via
Investor Brand Network
Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma
February 06, 2025
From
Kairos Pharma, Ltd.
Via
Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at AACR-JCA Joint Conference on Innovative Cancer Therapy
January 28, 2025
Via
Investor Brand Network
Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
January 28, 2025
From
Kairos Pharma, Ltd
Via
Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2024 Milestones and 2025 Clinical Outlook
January 21, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Kairos Pharma Provides Business Update and Outlook into 2025
January 21, 2025
From
Kairos Pharma, Ltd
Via
Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Present at Lytham Partners Investor Healthcare Summit
January 07, 2025
Via
Investor Brand Network
Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit
January 07, 2025
From
Kairos Pharma, Ltd
Via
Business Wire
InvestorNewsBreaks – EF Hutton Provided ‘Buy’ Rating, $9.00 Price Target in Kairos Pharma, Ltd. (NYSE: KAPA) Recent Research Report
December 20, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Kairos Pharma, Ltd. (NYSE: KAPA) Receives ‘Buy’ Recommendation, $12.00 Price Target in Rodman & Renshaw Research Report
December 18, 2024
Via
Investor Brand Network
Kairos Pharma to Participate in The Microcap Conference in January 2025
December 16, 2024
Via
ACCESSWIRE
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present Growth Strategy at The Microcap Conference 2025
December 16, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Expands Phase 2 Trial of ENV105 to City of Hope for Prostate Cancer Therapy
December 03, 2024
Via
Investor Brand Network
Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial
December 03, 2024
From
Kairos Pharma, Ltd
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.